In re P3 Health Group Holdings, LLC

Court of Chancery of Delaware·Decided October 31, 2022·No. C.A. No. 2021-0518-JTL·Published

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

IN RE P3 HEALTH GROUP ) Consol. C.A. No. 2021-0518-JTL HOLDINGS, LLC )

MEMORANDUM OPINION

Date Submitted: July 13, 2022 Date Decided: October 31, 2022

Bruce E. Jameson, Corinne Elise Amato, Eric J. Juray, Elizabeth Wang, PRICKETT, JONES & ELLIOTT, P.A., Wilmington, Delaware; Craig Carpenito, Richard H. Walker, Samuel C. Cortina, KING & SPALDING LLP, New York, New York; Counsel for Hudson Vegas Investment SPV, LLC.

William M. Lafferty, Kevin M. Coen, Ryan D. Stottmann, Sara Toscano, MORRIS, NICHOLS, ARSHT & TUNNELL LLP, Wilmington, Delaware; Counsel for Jessica Puathasnanon and P3 Health Group Holdings, LLC.

Kevin R. Shannon, Christopher N. Kelly, Daniel M. Rusk IV, POTTER ANDERSON & CORROON LLP, Wilmington, Delaware; William K. Kane, J, SHEPPARD MULLIN RICHTER & HAMPTON LLP, Chicago, Illinois; James C. Wald, SHEPPARD MULLIN RICHTER & HAMPTON LLP, Los Angeles, California; Counsel for Chicago Pacific Founders Fund, L.P., CPF P3 Splitter, LLC, Greg Kazarian, Larry Leisure, Mary Tolan, and Sameer Mathur.

Elena C. Norman, Paul J. Loughman, Lakshmi A. Muthu, Alberto E. Chávez, YOUNG CONAWAY STARGATT & TAYLOR LLP, Wilmington, Delaware; Counsel for Sherif W. Abdou, Amir Bacchus, Gary Garrett, Lorie Glisson, Taylor Leavitt, and Tom Price.

LASTER, V.C.

Hudson Vegas Investment SPV, LLC (“Hudson”) was a minority investor in P3 Health Group Holdings, LLC (the “Company” or “P3”). In this litigation, Hudson asserts various claims based on a business combination between the Company and a special purpose acquisition company, commonly known as a SPAC.

In Counts I–IV of its complaint, Hudson asserts claims for breach of the Company’s limited liability company agreement (the “LLC Agreement”). Hudson brings those claims against the SPAC, the Company, and the Company’s controlling investor, Chicago Pacific Founders Fund, L.P (“Chicago Pacific”). Each has moved to dismiss under Rule 12(b)(6), arguing that none of Hudson’s theories state claims on which relief can be granted.

The SPAC is not a party to the LLC Agreement, so its motion is granted. Chicago Pacific is a party to the LLC Agreement in its capacity as a member, but does not owe any of the obligations that Hudson seeks to enforce. Its motion is granted also.

The outcome for the Company is mixed. Hudson contends that the Company breached the LLC Agreement in fourteen different ways:

• Three theories focus on the composition of the board of directors of the post-merger entity.

• One theory focuses on an alleged agreement to combine the Company with another Chicago Pacific portfolio company.

• Two theories focus on Hudson’s right to a first-priority distribution of $50 million.

• Four theories focus on the use of blocker transactions to enable Chicago Pacific to obtain favorable tax treatment for part of its share of the merger consideration.

• Two theories focus on the Company’s refusal to honor an option that entitles Hudson to buy additional equity in the Company.

• Two theories focus on how Hudson’s representatives on the Company’s governing board were treated during the process that led to the merger.

Some of Hudson’s claims survive pleading-stage analysis. Others are dismissed.

I. FACTUAL BACKGROUND The facts are drawn from the currently operative complaint and the documents it incorporates by reference. At this stage of the proceedings, the complaint’s allegations are assumed to be true, and the plaintiff receives the benefit of all reasonable inferences.1 A. The Company Before the transaction challenged in this litigation, the Company was a Delaware LLC that engaged in the business of population healthcare management. That concept involves providing administrative support to physicians and other healthcare providers so that patients receive more cost-effective healthcare. At the time of the events giving rise to this litigation, the Company conducted business in Nevada, Arizona, Florida, and Oregon.

Chicago Pacific is a private equity fund focused on the healthcare industry. Before the transaction challenged in this litigation, the Company was one of Chicago Pacific’s portfolio companies. The fund provided the initial capital for the Company and referred

Citations in the form “Ex. —” refer to documents attached to the amended

1

complaint. Citations in the form “AC ¶ —” refer to allegations in Hudson’s amended complaint. Citations in the form “PX __” refer to exhibits from Hudson’s previous motion for a preliminary injunction.

to itself as the Company’s founding investor. The fund held Class A units that carried special governance rights, including the right to appoint members to the Company’s board of managers (the “Board”). Through a combination of governance rights, Board representation, and other sources of influence, Chicago Pacific controlled the Company.

Sherif W. Abdou and Amir Bacchus are physicians and entrepreneurs who co-

founded the Company. Abdou became CEO. Bacchus took on a senior officer role that the complaint does not identify. They held Class B units that gave them the right to appoint two members of the Board. They appointed themselves.

The Company issued Class C units to other members of the Company’s management team. The holders of those units had the right to appoint one manager. They appointed a Company executive named Lorie Glisson.

In 2019, Hudson invested $50 million in the Company. Hudson describes itself as “a Delaware limited liability company led by a management team with a history of building successful healthcare companies.” AC ¶ 6. In return for its investment, Hudson received Class D units that carried special governance rights, including the right to designate two members of the Board. Hudson designated John Bradburn and Joseph Straus (the “Hudson Managers”).

In 2020, Leavitt Equity Partners acquired a portion of Chicago Pacific’s Class A units. Chicago Pacific agreed that Leavitt could designate one of the managers allocated to the Class A units. Taylor Leavitt became that manager.

During the time relevant to the complaint, Chicago Pacific had the right to appoint five members of the Board (the “Chicago Pacific Managers”). Chicago Pacific appointed

three principals of the fund: Greg Kazarian, Mary Tolan, and Larry Leisure. Chicago Pacific also appointed two outsiders: Gary Garrett and Tom Price. Two of the Chicago Pacific Managers held positions that gave them additional authority: Tolan served as Chair of the Board, and Kazarian served as the Company’s Chief Strategic Officer. B. The Original Deal Structure In August 2020, the Company began exploring ways to access the public markets.

On September 1, various representatives of the Company, including several members of the Board, held a Zoom meeting to review the Company’s strategic alternatives.

One of the strategic alternatives was to combine the Company with another Chicago Pacific portfolio company known as MyCare. The combined company would have greater scale and could access the public markets more effectively than either company alone.

On November 1, 2020, Abdou, Bacchus, and Tolan met with Greg Wasson, the former CEO of Walgreens, about a transaction with a SPAC that Wasson would sponsor through his family office. The distinction between Wasson and his family office is not important to this decision, which for simplicity refers to Wasson.

By late November 2020, the Company, Chicago Pacific, and Wasson were discussing a potential three-way merger involving the Company, MyCare, and a Wasson- sponsored SPAC (the “Original Deal Structure”). They entered into a non-disclosure agreement, shared confidential information, and developed detailed financial models for the post-transaction company.

Free access — add to your briefcase to read the full text and ask questions with AI

In re P3 Health Group Holdings, LLC, (Del. Ct. App. 2022).

In re P3 Health Group Holdings, LLC (In re P3 Health Group Holdings, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Aspen Advisors LLC v. United Artists Theatre Co.
843 A.2d 697 (Court of Chancery of Delaware, 2004)
Lorillard Tobacco Co. v. American Legacy Foundation
903 A.2d 728 (Supreme Court of Delaware, 2006)
Henshaw v. American Cement Corporation
252 A.2d 125 (Court of Chancery of Delaware, 1969)
Dunlap v. State Farm Fire & Casualty Co.
878 A.2d 434 (Supreme Court of Delaware, 2005)
Gotham Partners, L.P. v. Hallwood Realty Partners, L.P.
817 A.2d 160 (Supreme Court of Delaware, 2002)
Katz v. Oak Industries Inc.
508 A.2d 873 (Court of Chancery of Delaware, 2008)
E.I. Du Pont De Nemours & Co. v. Shell Oil Co.
498 A.2d 1108 (Supreme Court of Delaware, 1985)
Elliott Associates, L.P. v. Avatex Corp.
715 A.2d 843 (Supreme Court of Delaware, 1998)
Nemec v. Shrader
991 A.2d 1120 (Supreme Court of Delaware, 2010)
Rhone-Poulenc Basic Chemicals Co. v. American Motorists Insurance Co.
616 A.2d 1192 (Supreme Court of Delaware, 1992)
Kuroda v. SPJS Holdings, L.L.C.
971 A.2d 872 (Court of Chancery of Delaware, 2009)
Gilbert v. El Paso Co.
490 A.2d 1050 (Court of Chancery of Delaware, 1984)
Price v. E.I. DuPont De Nemours & Co.
26 A.3d 162 (Supreme Court of Delaware, 2011)
Sassano v. CIBC World Markets Corp.
948 A.2d 453 (Court of Chancery of Delaware, 2008)
Aspen Advisors LLC v. United Artists Theatre Co.
861 A.2d 1251 (Supreme Court of Delaware, 2004)
Lonergan v. EPE HOLDINGS LLC
5 A.3d 1008 (Court of Chancery of Delaware, 2010)
Allen v. El Paso Pipeline GP Company, L.L.C.
113 A.3d 167 (Court of Chancery of Delaware, 2014)
Federal United Corp. v. Havender
11 A.2d 331 (Supreme Court of Delaware, 1940)